Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24


Using a multistage genetic association approach comprising 7,480 affected individuals and 7,779 controls, we identified markers in chromosomal region 8q24 associated with colorectal cancer. In stage 1, we genotyped 99,632 SNPs in 1,257 affected individuals and 1,336 controls from Ontario. In stages 2–4, we performed serial replication studies using 4,024 affected individuals and 4,042 controls from Seattle, Newfoundland and Scotland. We identified one locus on chromosome 8q24 and another on 9p24 having combined odds ratios (OR) for stages 1–4 of 1.18 (trend; P = 1.41 × 10−8) and 1.14 (trend; P = 1.32 × 10−5), respectively. Additional analyses in 2,199 affected individuals and 2,401 controls from France and Europe supported the association at the 8q24 locus (OR = 1.16, trend; 95% confidence interval (c.i.): 1.07–1.26; P = 5.05 × 10−4). A summary across all seven studies at the 8q24 locus was highly significant (OR = 1.17, c.i.: 1.12–1.23; P = 3.16 × 10−11). This locus has also been implicated in prostate cancer1,2,3.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Figure 1: Study scheme.
Figure 2: Odds ratios associated with an additional copy of allele A at rs1050477 or allele A at rs719725 in samples of affected individuals and controls from our four-stage analysis and validation in several populations, assuming a log-additive impact on disease risk.
Figure 3: LD and locus map of 8q24.


  1. Gudmundsson, J. et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat. Genet. 39, 631–637 (2007).

    Article  CAS  Google Scholar 

  2. Haiman, C.A. et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat. Genet. 39, 638–644 (2007).

    Article  CAS  Google Scholar 

  3. Yeager, M. et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat. Genet. 39, 645–649 (2007).

    Article  CAS  Google Scholar 

  4. Lichtenstein, P. et al. Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark and Finland. N. Engl. J. Med. 343, 78–85 (2000).

    Article  CAS  Google Scholar 

  5. Cotterchio, M. et al. Ontario familial colon cancer registry: methods and first-year response rates. Chronic Dis. Can. 21, 81–86 (2000).

    CAS  Google Scholar 

  6. Fan, J.B. et al. Illumina universal bead arrays. Methods Enzymol. 410, 57–73 (2006).

    Article  CAS  Google Scholar 

  7. Greenwood, C.M.T., Rangrej, J. & Sun, L. Optimal selection of markers for validation from genome-wide association studies. Genet. Epidemiol. 31, 396–407 (2007).

    Article  Google Scholar 

  8. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control. Clin. Trials 7, 177–188 (1986).

    Article  CAS  Google Scholar 

  9. Amundadottir, L.T. et al. A common variant associated with prostate cancer in European and African populations. Nat. Genet. 38, 652–658 (2006).

    Article  CAS  Google Scholar 

  10. Wang, Y. et al. Allele quantification using molecular inversion probes (MIP). Nucleic Acids Res. 33, e183 (2005).

    Article  Google Scholar 

  11. Nicolae, D.L., Wen, X., Voight, B.F. & Cox, N.J. Coverage and characteristics of the Affymetrix GeneChip Human Mapping 100K SNP set. PLoS Genet. 2, e67 (2006).

    Article  Google Scholar 

  12. Sasieni, P.D. From genotypes to genes: doubling the sample size. Biometrics 53, 1253–1261 (1997).

    Article  CAS  Google Scholar 

  13. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. Royal Stat. Soc. B 59, 289–300 (1995).

    Google Scholar 

Download references


The authors thank D. Daftary and T. Selander at the Mount Sinai Hospital Biorepository for technical and administrative assistance with OFCCR samples. We also are grateful to A. Bélisle, S. Roland, M.-C. Tessier and D. Vincent of the McGill University and Génome Québec Innovation Centre for technical genotyping assistance. We acknowledge all those involved in recruitment and assembly of the biological and data resources of the Colorectal Cancer Genetic Susceptibility (COGS) study and the Scottish Colorectal Cancer Study (SOCCS), including the Edinburgh Wellcome Trust Clinical Research Facility and also the Family Practitioner Services Department, the Cancer Intelligence Unit of the Information and Statistics Division (ISD) and Scottish Cancer Registry Cancer, all of the Scottish Central National Health Service (NHS). C. Bonithon-Kopp, A. Pariente, B. Nalet and J. Lafon (Group d'Etude des Adenomas) and members of the Association Nationale des Gastroenterologues des Hopitaux Généraux. For administrative assistance, we acknowledge L. Blahut (Cancer Care Ontario). We are grateful to the nursing, laboratory and office staff throughout Edinburgh, at the Wellcome Trust Clinical Research Facility and at the central Scottish NHS departments, including Cancer Registry and the Scottish Cancer Intelligence Unit of ISD. Cancer Care Ontario, as the host organization to the ARCTIC Genome Project, acknowledges that this Project was funded by Genome Canada through the Ontario Genomics Institute, by Génome Québec, the Ministère du Dévelopement Économique et Régional et de la Recherche du Québec and the Ontario Institute for Cancer Research (B.W.Z., T.J.H., C.M.T.G, S.G. and M.C.). This work was supported through collaboration and cooperative agreements with the Colon Cancer Family Registry and principal investigators supported by the US National Cancer Institute, US National Institutes of Health under RFA CA-95-011, including S.G. at the Ontario Registry for Studies of Familial Colorectal Cancer (U01 CA076783) and J.P. at the Seattle Colorectal Cancer Family Registry (U01 CA074794). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating institutions or investigators in the Colon Familial Registry, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government or the Colon CFR. This work was supported through collaboration and cooperative agreement with the Newfoundland Familial Colon Cancer Registry at the Memorial University of Newfoundland (B.Y., R.G., J.G.). The work in Scotland was supported by Cancer Research UK (C348/A3758, C48/A6361), the UK Medical Research Council (G0000657-53203) and the Scottish Executive Chief Scientist's Office (K/OPR/2/2/D333, CSO CZB/4/94) (M.D.) and by a Centre Grant from the Digestive Disorders Foundation ( Support in France came from the French Ministry of Research, Fondation de France (S.O., C.B.P.), Projet Hospitalier de Researche Clinique (PHRC) AOM01-006 (G.T.), Ligue Nationale contre le Cancer (G.T.), Groupement des Enterprises Francaises dans la Lutte contre le Cancer (GEFLUC) (S.B.) and the European Commission (E.R.). Support is acknowledged from the National Program for Complex Data Structures (Canada) (R.K.) and the Centre for Applied Genomics (Toronto) (C.G.).

Author information

Authors and Affiliations



B.W.Z., C.M.T.G., R.K., S.G., M.C. and T.J.H. devised and executed the original study design and prepared this manuscript. J.R., A.T., S.M.F., J.P., S.O., T.C., E.C., V.F., P.L., S.S., S.R., J.-F.O., F.R. and A.M. assisted in data analysis. R.S., P.C., S.B., A.M.O., G.Z., M.J., J.M., B.Y., R.G., J.G., M.E.M.P., H.C., H.B., M.S., E.T., C.B.-P., B.B., E.R., S.K. and S.J.C. provided insights and G.T., M.G.D., J.P., P.N. and E.P. assisted in sample procurement and study design and interpretation. A.T., S.M.F., J. Prendergast, M.E.M.P., H.C. and M.G.D. designed and undertook stages 3 and 4 of the study using the Scottish sample and data resource and contributed to writing the manuscript.

Corresponding author

Correspondence to Thomas J Hudson.

Ethics declarations

Competing interests

B.W.Z. is the founder and equity holder of Arctic Dx, a new Canadian biotechnology company that has received a license in the field of diagnostics for intellectual property generated by several Canadian institutions involved in this research. Arctic Dx currently has no financiers or employees.

Supplementary information

Supplementary Text and Figures

Supplementary Table 1, Supplementary Table 3, Supplementary Table 4, Supplementary Figure 1, Supplementary Methods (PDF 151 kb)

Supplementary Table 2

Phase 2 validation genotyping at 76 sites. (XLS 157 kb)

Supplementary Table 5

Selected SNPs genotyped using the Illumina GoldenGate Assay in stage 1 of the ARCTIC project. (XLS 197 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Zanke, B., Greenwood, C., Rangrej, J. et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet 39, 989–994 (2007).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing